Developer docs
API playgroundTry for free, no card

Search company profiles

BiolineRx

Full company profile

uuid0002jjy

Namestring
BiolineRx
Legal namestring
BioLineRx Ltd.
Websiteurl
biolinerx.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

BioLineRx Ltd. is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, listed on NASDAQ (BLRX) and TASE. The company focuses on developing therapeutics for oncology and rare diseases, anchored by two technology platforms: CXCR4 inhibition via motixafortide and TET2 pathway activation via GLIX1. Its commercial asset, APHEXDA (motixafortide), is an FDA-approved subcutaneous CXCR4 antagonist for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation.

The company's pipeline includes motixafortide in Phase 2b development for first-line metastatic pancreatic cancer (CheMo4METPANC trial co-supported with Regeneron and Columbia University) and Phase 1 evaluation for sickle cell disease stem cell mobilization with St. Jude and Washington University. GLIX1, a first-in-class oral small molecule restoring TET2 activity to selectively kill cancer cells, entered Phase 1/2a trials in glioblastoma in March 2026 under a joint venture with Hemispherian AS. USPTO patent protection on GLIX1 extends through 2040 across cancer types where cytidine deaminase is not over-expressed (over 90% of cancers).

BioLineRx operates an asset-light, partner-driven commercial model. APHEXDA is commercialized globally ex-Asia through an exclusive license to Ayrmid Ltd. (parent of Gamida Cell) and in Asia through Gloria Biosciences, generating royalty revenue of $480,000 in Q1 2026 (up 88% YoY). FY2025 revenue was $1.2M with a net loss of $2M. The company held $17.4M in cash as of Q1 2026, providing runway into H1 2027. Trial execution and pipeline progression are largely outsourced to academic medical centers (Columbia, NYU Langone, Northwestern, Moffitt, Washington University, St. Jude), with a lean internal team of 51-100 employees concentrated in clinical operations, regulatory affairs, and chemistry.

Short descriptiontext

BioLineRx is a Jerusalem-based clinical-stage biopharmaceutical company developing oncology and rare disease therapies, with FDA-approved APHEXDA (motixafortide) for multiple myeloma stem cell mobilization and pipeline assets GLIX1 for glioblastoma and motixafortide in pancreatic cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersModi'in, Israel
HQ citystring
Modi'in
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
oncology therapeutics, stem cell mobilization, biopharmaceutical drug development, CXCR4 antagonists, rare disease treatments
Industry4 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1APHEXDA Product Sales
TypeLicensing Royalties
Description

Revenue generated from commercialization of APHEXDA (motixafortide) for stem cell mobilization in multiple myeloma patients through licensing partner Ayrmid Ltd.

in.investing.com
2Royalties from APHEXDA
TypeLicensing Royalties
Description

Q1 2026 revenue of $480,000, up 88% year-over-year, driven by increased royalties from APHEXDA commercialization with Ayrmid Ltd. and Gloria Biosciences.

in.investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1APHEXDA
Description

FDA-approved stem cell mobilization product (motixafortide) for multiple myeloma patients

biolinerx.com
Core offering1 text field

BioLineRx develops and out-licenses novel biopharmaceutical therapies for oncology and rare diseases. Its commercial product APHEXDA (motixafortide) is a CXCR4 antagonist approved by the FDA for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. The pipeline extends motixafortide into metastatic pancreatic cancer and sickle cell disease, and adds GLIX1, a first-in-class oral TET2 activator in Phase 1/2a for glioblastoma and other solid tumors. Revenue is generated through licensing royalties from commercialization partners Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 6.5 months median overall survival vs 4.7 months historical data in metastatic pancreatic cancer (COMBAT study)
+5 more records
Product overview1 text field

BiolineRx is a clinical-stage biopharmaceutical company advancing an innovative pipeline of therapeutics for patients with cancer and rare diseases. The company's portfolio includes APHEXDA (motixafortide), an FDA-approved stem cell mobilization agent commercialized by partner Ayrmid Ltd., as well as motixafortide which is further being developed for pancreatic cancer (Phase 2) and sickle cell disease (Phase 1). The lead development asset is GLIX1, a first-in-class oral small molecule targeting DNA damage response via TET2 restoration, currently in Phase 1/2a clinical trials for glioblastoma. BiolineRx leverages full-spectrum drug development capabilities including chemistry, analytics, nonclinical and clinical development, and commercialization expertise.

Product and service2 records
1APHEXDA (motixafortide)
CategoryApproved Biopharmaceutical / CXCR4 Antagonist
Description

APHEXDA (motixafortide) is an FDA-approved CXCR4 antagonist administered as a subcutaneous injection for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. It is BioLineRx's only commercially approved product, generating royalty revenue through the licensing partner Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia). The same molecule (motixafortide) is also being developed in pipeline indications including metastatic pancreatic cancer (Phase 2b CheMo4METPANC trial) and sickle cell disease stem cell mobilization for gene therapy (Phase 1, in collaboration with Washington University and St. Jude).

2GLIX1
CategoryInvestigational Biopharmaceutical / TET2 Pathway Activator
Description

GLIX1 is a first-in-class oral small molecule that targets DNA damage repair by restoring TET2 activity, promoting selective cancer-cell killing while sparing normal cells. It is brain-penetrant and in Phase 1/2a clinical development for glioblastoma and other high-grade gliomas, with potential applications across approximately 90% of cancer types where cytidine deaminase is not over-expressed. The asset is being advanced through the BioLineRx-Hemispherian joint venture established in Q3 2025.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

Collaboration agreement to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response by restoring TET2 activity. A joint venture was established in Q3 2025 to advance GLIX1 clinical development for glioblastoma and other cancers. First-in-human Phase 1/2a trial initiated March 2026 at NYU Langone Health, Northwestern University, and Moffitt Cancer Center.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-01
Description

License agreement granting Ayrmid exclusive rights to develop and commercialize APHEXDA (motixafortide) across all indications except solid tumor indications, in all territories other than Asia. Ayrmid leads US commercialization of the approved stem cell mobilization product and the St. Jude sickle cell disease program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Clinical trial collaboration for multi-center Phase 1 clinical trial evaluating safety, tolerability, and feasibility of single-agent motixafortide for mobilization and collection of CD34+ hematopoietic stem cells in 12 patients aged 18+ with sickle cell disease. Through APHEXDA development agreement with Ayrmid, Gamida Cell leads this program.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-10-01
Description

Agreement for development and commercialization of motixafortide across all indications in Asia. GloriaBio plans to lead a bridging study to support potential approval and commercialization of motixafortide in stem cell mobilization for autologous transplantation in patients with multiple myeloma in China, and a randomized Phase 2 trial in first-line pancreatic cancer with zimberelimab and chemotherapy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sponsor of CheMo4METPANC randomized Phase 2b clinical trial evaluating motixafortide in combination with PD-1 inhibitor cemiplimab (LIBTAYO) and standard chemotherapy vs chemotherapy alone in 108 first-line metastatic pancreatic cancer patients. Trial equally supported by BioLineRx and Regeneron.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-supporter of the CheMo4METPANC randomized Phase 2b clinical trial in first-line metastatic pancreatic cancer, equally sharing development costs with BioLineRx.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BiolineRx

Oncology Biopharmaceuticalsbiolinerx.com

BioLineRx is a Jerusalem-based clinical-stage biopharmaceutical company developing oncology and rare disease therapies, with FDA-approved APHEXDA (motixafortide) for multiple myeloma stem cell mobilization and pipeline assets GLIX1 for glioblastoma and motixafortide in pancreatic cancer.

What BiolineRx does

BioLineRx Ltd. is a clinical-stage biopharmaceutical company headquartered in Jerusalem, Israel, listed on NASDAQ (BLRX) and TASE. The company focuses on developing therapeutics for oncology and rare diseases, anchored by two technology platforms: CXCR4 inhibition via motixafortide and TET2 pathway activation via GLIX1. Its commercial asset, APHEXDA (motixafortide), is an FDA-approved subcutaneous CXCR4 antagonist for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation.

The company's pipeline includes motixafortide in Phase 2b development for first-line metastatic pancreatic cancer (CheMo4METPANC trial co-supported with Regeneron and Columbia University) and Phase 1 evaluation for sickle cell disease stem cell mobilization with St. Jude and Washington University. GLIX1, a first-in-class oral small molecule restoring TET2 activity to selectively kill cancer cells, entered Phase 1/2a trials in glioblastoma in March 2026 under a joint venture with Hemispherian AS. USPTO patent protection on GLIX1 extends through 2040 across cancer types where cytidine deaminase is not over-expressed (over 90% of cancers).

BioLineRx operates an asset-light, partner-driven commercial model. APHEXDA is commercialized globally ex-Asia through an exclusive license to Ayrmid Ltd. (parent of Gamida Cell) and in Asia through Gloria Biosciences, generating royalty revenue of $480,000 in Q1 2026 (up 88% YoY). FY2025 revenue was $1.2M with a net loss of $2M. The company held $17.4M in cash as of Q1 2026, providing runway into H1 2027. Trial execution and pipeline progression are largely outsourced to academic medical centers (Columbia, NYU Langone, Northwestern, Moffitt, Washington University, St. Jude), with a lean internal team of 51-100 employees concentrated in clinical operations, regulatory affairs, and chemistry.

BiolineRx firmographics

Firmographics
Name
BiolineRx
Legal name
BioLineRx Ltd.
Website
https://biolinerx.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
BioLineRx is a Jerusalem-based clinical-stage biopharmaceutical company developing oncology and rare disease therapies, with FDA-approved APHEXDA (motixafortide) for multiple myeloma stem cell mobilization and pipeline assets GLIX1 for glioblastoma and motixafortide in pancreatic cancer.
Ownership category
akta.pro rank

BiolineRx industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAIAC
Rare Oncology & Hematologic Malignancy Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Oncology therapeutics
  • Stem cell mobilization
  • Biopharmaceutical drug development
  • CXCR4 antagonists
  • Rare disease treatments

Where BiolineRx is headquartered

Location

Headquarters

HQ city
Modi'in
HQ country
Israel
HQ region
Middle East

Markets served

BiolineRx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. APHEXDA Product Sales: Revenue generated from commercialization of APHEXDA (motixafortide) for stem cell mobilization in multiple myeloma patients through licensing partner Ayrmid Ltd.
  2. Royalties from APHEXDA: Q1 2026 revenue of $480,000, up 88% year-over-year, driven by increased royalties from APHEXDA commercialization with Ayrmid Ltd. and Gloria Biosciences.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

BiolineRx product offering

Product offering

Core offering

BioLineRx develops and out-licenses novel biopharmaceutical therapies for oncology and rare diseases. Its commercial product APHEXDA (motixafortide) is a CXCR4 antagonist approved by the FDA for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. The pipeline extends motixafortide into metastatic pancreatic cancer and sickle cell disease, and adds GLIX1, a first-in-class oral TET2 activator in Phase 1/2a for glioblastoma and other solid tumors. Revenue is generated through licensing royalties from commercialization partners Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia).

Product overview

BiolineRx is a clinical-stage biopharmaceutical company advancing an innovative pipeline of therapeutics for patients with cancer and rare diseases. The company's portfolio includes APHEXDA (motixafortide), an FDA-approved stem cell mobilization agent commercialized by partner Ayrmid Ltd., as well as motixafortide which is further being developed for pancreatic cancer (Phase 2) and sickle cell disease (Phase 1). The lead development asset is GLIX1, a first-in-class oral small molecule targeting DNA damage response via TET2 restoration, currently in Phase 1/2a clinical trials for glioblastoma. BiolineRx leverages full-spectrum drug development capabilities including chemistry, analytics, nonclinical and clinical development, and commercialization expertise.

Differentiator

Problem solved

Functional benefit

Brands

  • APHEXDA: FDA-approved stem cell mobilization product (motixafortide) for multiple myeloma patients

Products and services

  • APHEXDA (motixafortide) APHEXDA (motixafortide) is an FDA-approved CXCR4 antagonist administered as a subcutaneous injection for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. It is BioLineRx's only commercially approved product, generating royalty revenue through the licensing partner Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia). The same molecule (motixafortide) is also being developed in pipeline indications including metastatic pancreatic cancer (Phase 2b CheMo4METPANC trial) and sickle cell disease stem cell mobilization for gene therapy (Phase 1, in collaboration with Washington University and St. Jude).
  • GLIX1 GLIX1 is a first-in-class oral small molecule that targets DNA damage repair by restoring TET2 activity, promoting selective cancer-cell killing while sparing normal cells. It is brain-penetrant and in Phase 1/2a clinical development for glioblastoma and other high-grade gliomas, with potential applications across approximately 90% of cancer types where cytidine deaminase is not over-expressed. The asset is being advanced through the BioLineRx-Hemispherian joint venture established in Q3 2025.

Quantifiable outcome

  • 6.5 months median overall survival vs 4.7 months historical data in metastatic pancreatic cancer (COMBAT study)
  • +5 more outcomes

Companies that use BiolineRx

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles2 records

BiolineRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BiolineRx partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Hemispherian AScoreStrategic or Co-development Partner · 24 November 2025Collaboration agreement to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response by restoring TET2 activity. A joint venture was established in Q3 2025 to advance GLIX1 clinical development for glioblastoma and other cancers. First-in-human Phase 1/2a trial initiated March 2026 at NYU Langone Health, Northwestern University, and Moffitt Cancer Center.
  • Ayrmid Ltd. (Gamida Cell Ltd.)coreOEM/ Whitelabel/ Licensing Partner · 1 November 2024License agreement granting Ayrmid exclusive rights to develop and commercialize APHEXDA (motixafortide) across all indications except solid tumor indications, in all territories other than Asia. Ayrmid leads US commercialization of the approved stem cell mobilization product and the St. Jude sickle cell disease program.
  • St. Jude Children's Research HospitalminorStrategic or Co-development Partner · 1 May 2024Clinical trial collaboration for multi-center Phase 1 clinical trial evaluating safety, tolerability, and feasibility of single-agent motixafortide for mobilization and collection of CD34+ hematopoietic stem cells in 12 patients aged 18+ with sickle cell disease. Through APHEXDA development agreement with Ayrmid, Gamida Cell leads this program.
  • Gloria BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 1 October 2023Agreement for development and commercialization of motixafortide across all indications in Asia. GloriaBio plans to lead a bridging study to support potential approval and commercialization of motixafortide in stem cell mobilization for autologous transplantation in patients with multiple myeloma in China, and a randomized Phase 2 trial in first-line pancreatic cancer with zimberelimab and chemotherapy.
  • Columbia UniversitycoreStrategic or Co-development PartnerSponsor of CheMo4METPANC randomized Phase 2b clinical trial evaluating motixafortide in combination with PD-1 inhibitor cemiplimab (LIBTAYO) and standard chemotherapy vs chemotherapy alone in 108 first-line metastatic pancreatic cancer patients. Trial equally supported by BioLineRx and Regeneron.
  • RegeneronminorStrategic or Co-development PartnerCo-supporter of the CheMo4METPANC randomized Phase 2b clinical trial in first-line metastatic pancreatic cancer, equally sharing development costs with BioLineRx.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

BiolineRx competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BiolineRx social profiles

Digital presence

BiolineRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BiolineRx leadership team

Management profile

Number of profiles

Profiles19 records

BiolineRx subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BiolineRx funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BiolineRx M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiolineRx

What does BiolineRx do?

BioLineRx develops and out-licenses novel biopharmaceutical therapies for oncology and rare diseases. Its commercial product APHEXDA (motixafortide) is a CXCR4 antagonist approved by the FDA for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous transplantation. The pipeline extends motixafortide into metastatic pancreatic cancer and sickle cell disease, and adds GLIX1, a first-in-class oral TET2 activator in Phase 1/2a for glioblastoma and other solid tumors. Revenue is generated through licensing royalties from commercialization partners Ayrmid Ltd. (US, non-solid-tumor indications) and Gloria Biosciences (Asia).

Is BiolineRx a public or private company?

BiolineRx is a public company. It is classified as public and is currently operating.

When was BiolineRx founded?

BiolineRx was founded in 2003. It employs 11 to 50 people.

Where is BiolineRx based?

BiolineRx is headquartered in Modi'in, Israel, in the Middle East region.

How does BiolineRx make money?

Two revenue lines are on record. APHEXDA Product Sales are the primary driver. The others are royalties from APHEXDA.

Does BiolineRx have an API?

No public API is recorded for BiolineRx.

What industry is BiolineRx in?

BiolineRx's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanBioLineRx sets Nov. 23 for Q3 earnings reportBioLineRx will report its unaudited third-quarter 2026 financial results on November 23, 2026, before U.S. markets open. CEO Philip Serlin will speak on an 8:30 a.m. EST conference call, with a live webcast and replay available. The company's lead asset GLIX1 is in Phase 1/2a trials for glioblastoma.PR NewswireBioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus CapitalBioLineRx sold its 14.4% royalty interest in APHEXDA to Soleus Capital for $5.6 million, excluding the original licensor's 3.6% share. Proceeds will fund GLIX1's Phase 1/2a trial and working capital, with the deal expected to close on November 30, 2026.Ticker ReportCritical Contrast: Genmab A/S (NASDAQ:GMAB) vs. BioLineRx (NASDAQ:BLRX)Genmab A/S and BioLineRx are compared on profitability, valuation, and analyst ratings. Genmab has higher revenue ($3.72B vs $1.18M), positive net margins (19.08% vs -502.08%), and a stronger consensus rating, while BioLineRx trades at a lower P/E. Genmab beats BioLineRx on 13 of 15 factors.Investing.comBioLineRx and Hemispherian to present GLIX1 data at SNO meetingBioLineRx and Hemispherian will present two GLIX1 abstracts at the 31st Society for Neuro-Oncology Annual Meeting in Philadelphia, November 12-15, 2026. The posters cover preclinical glioblastoma models and the Phase 1/2a trial for recurrent high-grade glioma, with the trial initiated in Q1 2026.Stock TitanBioLineRx to present 2 GLIX1 posters at SNOBioLineRx and Hemispherian will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting on November 13, 2026. The meeting is the 31st SNO Annual Meeting & Education Day.American Banking and Market NewsCritical Review: CRISPR Therapeutics (NASDAQ:CRSP) vs. BioLineRx (NASDAQ:BLRX)CRISPR Therapeutics outperforms BioLineRx on 11 of 15 factors, including institutional ownership and analyst ratings. CRISPR has a consensus price target of $67.94, implying 18.49% upside, while BioLineRx carries a sell rating. CRISPR's lower P/E ratio makes it the more affordable stock.Markets DailyBioLineRx (NASDAQ:BLRX) & CRISPR Therapeutics (NASDAQ:CRSP) Critical ReviewCRISPR Therapeutics and BioLineRx are compared on 15 factors, with CRISPR winning 11. CRISPR has a higher consensus rating, a $67.94 price target implying 22.55% upside, and 69.2% institutional ownership versus 1.6% for BioLineRx. CRISPR is also more profitable and trades at a lower P/E ratio.The future of tradingBioLineRx holds annual shareholder meetingBioLineRx held its annual shareholder meeting on Sept. 23, 2026. Shareholders reappointed three directors through 2029, adopted an increase in authorized share capital, and reappointed Kesselman & Kesselman as independent auditor for the year ending Dec. 31, 2026.Investing.comEarnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances By Investing.comBioLineRx reported Q2 2026 revenue of $0.3 million, flat year-over-year, and a net loss of $4.3 million. Its lead drug GLIX1 advanced through phase I/IIa testing at three academic centers with encouraging safety data. The company expects phase I data in the first half of 2027 and an interim futility analysis for its pancreatic cancer program later in 2026.MorningstarBioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateBioLineRx reported Q2 2026 results with a $4.3M net loss and $13.1M cash, and announced GLIX1 data showing potent activity in TMZ-resistant GBM and synergy with PARP inhibitors. The company plans to add an ovarian cancer arm to the Phase 2a expansion and entered a $3.75M offering expected to close August 31.